Azurity Pharmaceuticals
Specialty/reformulated branded generics (BiDil)
Privately held: no public share price · United States
Assets
(10 total)
10Total Assets
10Approved
0Phase 3 / Filed
0Phase 1–2 / Early
9Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
Aclidinium bromide(Tudorza Pressair) | Approved | Muscarinic acetylcholine receptor (M3)Small molecule | Chronic Obstructive Pulmonary Disease |
Aclidinium bromide/formoterol fumarate(Duaklir Pressair) | Approved | Muscarinic acetylcholine receptor (M3) · Beta-2 adrenergic receptorSmall molecule | Chronic Obstructive Pulmonary Disease |
| Approved | Glucocorticoid receptorSmall molecule | Asthma | |
Ferumoxytol(Feraheme) | Approved | IV iron replacement therapyOther | Chronic Kidney DiseaseIron Deficiency Anemia |
| Approved | Hydralazine/isosorbide dinitrate (fixed combination)Small molecule | Heart Failure | |
naltrexone/bupropion(Contrave) | Approved | Opioid receptor / dopamine (combination) · Dopamine/norepinephrine transporterSmall molecule | Obesity |
| Approved | 5-HT1B/1D receptorSmall molecule | Migraine | |
| Approved | 5-HT1B/1D receptor · Nonsteroidal Anti-inflammatory DrugSmall molecule | Migraine | |
| Approved | Voltage-gated sodium channels; GABA-A receptor; AMPA/kainate glutamate receptors; carbonic anhydraseSmall molecule | EpilepsyMigraineLennox-Gastaut Syndrome Focal Onset Seizures, Primary Generalized Tonic-Clonic Seizures | |
| Approved | Voltage-gated sodium and T-type calcium channelsSmall molecule | Epilepsy Focal Onset Seizures |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
US, FDA · Source ↗
Financial reports
No financial reports recorded.